Replies to post #362204 on Anavex Life Sciences Corp (AVXL)

[tradeherpete]

Thanks, Talon.

I’d say, “another one bites the dust,” but this one just keeps coming back and won’t stop biting.

And not suffering, in the pps department.

How does that work?

Must be their transparency and great CEO.

[nidan7500]

Curious and more curious, will we now begin to see a pattern of axx covering moves by those wanting to distance themselves from previous clinical positions soon to be seen/proven as complete science garbage?

IMO, the amyloid plaque herd cannot/will not peacefully co-exist in the Autophagy- S1R world . Lets hope the transition is loud and nasty and that it begins soon. We have all put up w/this sloppy CNS "science" for far too long already.

This is not the first time that papers authored by Wang have been called into question regarding data cited in the articles. Earlier this year, PLoS One retracted five papers that Wang co-authored. The papers were pulled following an in-depth investigation that revealed "serious concerns about the integrity and reliability of the results."

https://www.biospace.com/article/another-journal-retracts-paper-co-authored-by-cassava-sciences-scientific-adviser/?

utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsmi=215206067&_hsenc=p2ANqtz-9T_16nZgXDPDoe40JH_v4F4EZFSSceM1oUR2_weX132SXKU5kNhb82tsxaFO9L9RoLpiE47COQooqpY6u7nRDzLDX3tA&utm_content=215206067&utm_source=hs_email

[McMagyar]

Haha..
Ink blots.. haha.

Oh shorts suck so bad

[nidan7500]

Lies, lies and MORE LIES...HUH

The expose in the Times caused Cassava Sciences President and Chief Executive Officer Remi Barbier to rebut the claims in the report, calling the article "one-sided" and saying the venerable newspaper misrepresented his company's research by only using sources who were critical of the Texas-based company. Barbier also claimed that those who spoke with the Times maintain a negative bias about Cassava. Two, in particular, the Times relied on for its article are known to be shorting the company stock, he added at the time.

Both neuroscientists were behind a Citizen's Petition filed with the U.S. Food and Drug Administration that aimed to suspend the company's clinical research into simufilam. The neuroscientists suggested that Cassava's research included published images that appeared to have been manipulated using Photoshop or similar software. That petition was denied earlier this year after the journal Neuroscience announced that it could find no evidence to support claims of data manipulation in a 2005 paper authored by the company and its scientific collaborators.

Shares of Cassava are down slightly in premarket trading. The stock closed at $26.82 per share on Wednesday.

https://www.biospace.com/article/another-journal-retracts-paper-co-authored-by-cassava-sciences-scientific-adviser/?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsmi=215206067&_hsenc=p2ANqtz-9T_16nZgXDPDoe40JH_v4F4EZFSSceM1oUR2_weX132SXKU5kNhb82tsxaFO9L9RoLpiE47COQooqpY6u7nRDzLDX3tA&utm_content=215206067&utm_source=hs_email